Video

Reining in the Cost of Cancer Care

For High-Definition, Click

Rising healthcare costs represent a national challenge and a “call to action,” which requires collaboration across platforms to devise practical solutions while keeping patients’ best interests at heart, says Andrew L. Pecora, MD.

Oncology physicians share in this responsibility, says the doctor. He has been involved in the creation of the Cancer Outcomes Tracking Analysis (COTA), a health outcomes measurement and tracking tool that Pecora says enables physicians to achieve the “Goldilocks” target—neither too much care, nor too little.

Pecora says his fellow physicians have contributed to the development of the Centers for Medicare & Medicaid Services’ Oncology Care Model of improving value and reducing expense, along with other types of reimbursement models.

Related Videos
In this episode of OncChats: A Close Look at Clinical Trials in Oncology and Beyond, Dr Carvajal discusses the progress made in cancer clinical trials, with nearly 20,000 trials worldwide and over 80 FDA-approved cancer drugs since 2015, while also noting the challenges posed by the increasing complexity of therapies and trial protocols.
Marcella Ali Kaddoura, MD
Eunice S. Wang, MD
Marcella Ali Kaddoura, MD
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.
Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.
Cedric Pobel, MD